ClinicalTrials.gg
Status unknownNCT02722694Updated Sep 13, 2016

A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

A Phase 3 interventional study of Subcutaneous(SC) Abatacept and Placebo in Rheumatoid Arthritis (RA), sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-09-13.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Planned enrollment
16th of 63
360 · median 119
Started
2016
with 2 others
Phase 3
26 of 63
2 open now
Registered
45th of 63
by date
Lead sponsor
2 of 63
Jiangsu Simcere Pharmaceutical Co., Ltd.

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 16th largest by planned enrollment, is one of 3 that started in 2016, is one of 26 in phase 3, and was the 45th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate superior efficacy of abatacept 125mg administrated SC weekly comparing to placebo after 24 weeks treatment in Chinese subjects who have active rheumatoid arthritis, are receiving methotrexate and experiencing an inadequate response to methotrexate. This will be estimated by the proportion of subjects meeting the American College of Rheumatology (ACR) criteria for 20% improvement (ACR20).

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects are willing to participate in this study and sign ;
  • Subjects must meet the criteria of the America Rheumatism Association (1987) for the diagnosis of rheumatoid arthritis and ACR (1991) functional classes I, II or III;
  • Subjects must have had Rheumatoid Arthritis for at least 6 months;
  • Subjects who have inadequately response to MTX, must have been taking methotrexate for at least 3 months with minimal dose of 10 mg weekly, and at a stable dose for at least 28 days prior to randomization (Day 1). Methotrexate weekly dose as low as 7.5 mg is permitted for subjects who cannot tolerate higher dose, and the intolerance of higher dose than 7.5mg weekly should be well documented;
  • Subjects must have the following disease activity at randomization:

    1. 6 or more swollen joints(66 joint count);
    2. 8 or more tender joints(68 joint count); and
    3. C reactive protein (hsCRP) > 3 mg/L (based on the result of screening visit) or ESR ≥ 28mm/hr;
  • All DMARDs (except methotrexate) should be discontinued for at least 28 days prior to study randomization (Day 1), Leflunomide must have been discontinued ≥8 weeks (the subject can be washed-out with cholestyramine according to label recommendations);
  • Oral treatment must have been reduced to the prednisone ≤ 10 mg daily or equivalent for 28 days,and stabilized for at least 25 out of 28 days prior to randomization (Day 1). Corticosteroid administered by intra-articular (IA) or intramuscular (IM) will not be allowed 28 days prior to randomization (Day 1);
  • Stable NSAIDs are permitted;
  • Male and female subject ≥18 years old;
  • Women of (WOCBP) must have a negative pregnancy test within 24 hours prior to the start of study medication;

Exclusion criteria

Exclusion Criteria:

  • and male patients of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 10 weeks after the last dose of study medication;
  • Women who are pregnant or breast-feeding;
  • Women with a positive pregnancy test on enrollment or prior to study drug administration;
  • Subjects meet diagnosis criteria of other rheumatoid disease (e.g., systemic lupus erythematosus);
  • Subjects with active vasculitis of the major organ systems (except for subcutaneous rheumatoid nodules);
  • Current symptoms of severe, progressive or uncontrolled diseases of renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral. Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study;
  • Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection). Existing non-melanoma skin cell cancers must be removed prior to dosing. Subjects with carcinoma in situ, treated with definitive surgical intervention, are allowed;
  • Subjects who have a history of drug or alcohol abuse;
  • Subjects with any serious bacterial infection within the last 3 months (such as pneumonia or pyelonephritis, unless treated and resolved with antibiotics);
  • Subjects with serious, chronic or recurrent bacterial infection (such as recurrent pneumonia and chronic bronchiectasis);
  • Subjects at risk for tuberculosis (TB), Specially, :

    1. Having evidences of clinical, imaging or lab test of current active or latent pulmonary tuberculosis;
    2. Having active pulmonary tuberculosis during the past 3 years, even if had treated;
    3. Having history of active pulmonary tuberculosis more than 3 years ago, unless the appropriate duration and types of anti-tuberculosis drug is well documented;
  • Subjects with herpes zoster that resolved less than 2 months before enrollment;
  • Subjects with evidence (as assessed by the Investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of (HIV) infection;
  • Subjects are impaired, incapacitated, or incapable of completing study related assessment;
  • Hepatitis-B surface antigen-positive subjects.
  • antibody-positive subjects
  • HIV antibody-positive subjects
  • Subjects with any of the following laboratory values:

    1. \< 85 g/L
    2. white blood cell count \< 3,000/mm3(3×10\^9/L)
    3. \< 100,000/mm3(100×10\^9/L);
    4. \< 40 mL/min;
    5. Serum glutamic pyruvic transaminase (GPT or ) or glutamic oxaloacetic transaminase (GOT or AST)>2 times ;
    6. Any other laboratory test results that, in the opinion of the Investigator, might place the subject at unacceptable risk for participation in this study;
  • Subjects who have received treatment with rituximab at any time;
  • Subjects who had prior exposure to abatacept or CTLA4-Ig;
  • Subjects who have received treatment with any drug within 28 days (or less than 5 terminal half-lives of elimination) (whichever is longer);
  • Subjects currently (when signing ) treated with an anti-tumor necrosis factor (TNF) therapy, such as adalimumab and infliximab (within 8 weeks of the last dose), or etanercept (within 4 weeks of the last dose);
  • Subjects who discontinued an approved biologic RA therapy due to lack of efficacy in the past;
  • Subjects exposed to multiple (>3) approved biologic RA therapies in the past;
  • Subjects currently treated with anakinra unless a minimum 4-week has been completed before Day 1;
  • Subjects who received prior treatment with any investigational biologic not currently approved;
  • Subjects who had been exposed to any approved biologic within 4 weeks or 5 half-lives, whichever was longer;
  • Subjects are (when signing informed consent)receiving an investigational biologic RA therapy or an approved biologic RA therapy;
  • Subjects who have received any active vaccine within 3 months of the first dose of the study medication or plan to receive active vaccine during the study;
  • Prisoners or subjects who are involuntarily incarcerated;
  • Subjects who are compulsorily detained for treatment either a psychiatric or physical (e.g., infectious disease) illness;
  • Subjects who are illiterate.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Subcutaneous(SC) Abatacept

    Drug: Subcutaneous(SC) Abatacept · Drug: Methotrexate

  • Placebo comparator
    Placebo

    Other: Placebo · Drug: Methotrexate

Interventions

  • Subjects received 125mg weekly SC abatacept injections for 24 weeks. All subjects who complete 24 weeks double-blind treatment are eligible to enter open label period. During this period, subjects in placebo group will be switched to receive abatacept 125mg administered SC weekly till week 52. Subjects in abatacept group will continue to receive abatacept 125mg weekly.

    Also known as: Orencia

  • OtherPlacebo

    Subjects received weekly SC placebo injections for 24 weeks

  • All Subjects received backup Methotrexate treatment.

06

What researchers measure

Primary outcomes

  1. The proportion of subjects meeting ACR 20 at 24 weeks (Day 169)

    The ACR 20 definition of improvement is a 20% improvement from baseline in the number of tender and swollen joints, and a 20% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).

    Time frame: Day 169

Secondary outcomes

  1. The proportion of subject meeting Health Assessment Questionnaire Disability Index (HAQ-DI) improvement at 24 weeks (Day 169)

    The HAQ questionnaire includes 20 questions to assess physical function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The domain questions are evaluated on a 4-point scale: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ-DI response=an improvement of at least 0.3 units from baseline in HAQ-DI.

    Time frame: Day 169

  2. The proportion of subjects meeting ACR 50 at 24 weeks (Day 169)

    The ACR 50 definition of improvement is a 50% improvement from baseline in the number of tender and swollen joint counts, and a 50% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).

    Time frame: Day 169

  3. The proportion of subjects meeting ACR 70 at 24 weeks (Day 169)

    The ACR 70 definition of improvement is a 70% improvement from baseline in the number of tender and swollen joint counts, and a 70% improvement from baseline in 3 of the remaining 5 core set measures: participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function and acute phase reactant value (C-reactive protein).

    Time frame: Day 169

Other outcomes

  1. The mean change of disease activity score from baseline by measuring DAS28-CRP at 24 weeks (Day 169)

    The DAS28 index measures disease activity in rheumatoid arthritis and is a composite derived from the number of swollen/tender joints, laboratory tests of inflammation (C-reactive protein measured in mg/L), and participant assessment of global health (by marking a visual analog scale 100 mm line from "very good" to "very bad"). A higher DAS28 score indicates worse control of disease. High disease activity is \> 5.1, low disease activity is \< 3.2 and remission is \< 2.6.

    Time frame: Day 169

  2. The mean change of HAQ-DI from baseline at 24 weeks (Day 169)

    Time frame: Day 169

  3. Cmin of abatacept 125 mg administered SC weekly

    Time frame: Day1 to Day196 in double-blind period

  4. Cmax of abatacept 125 mg administered SC weekly

    Time frame: Day71 to Day78 in open-label period

  5. Area Under Curve (AUC) of abatacept 125 mg administered SC weekly

    Time frame: Day71 to Day78 in open-label period

  6. Anti-abatacept antibodies

    Time frame: Day1 to Day421

  7. Anti cytotoxic T lymphocyte-associated antigen-4(CTLA-4) antibodies

    Time frame: Day1 to Day421

07

Study locations

1 of 1 sites recruiting
  • Peking union medical college hospital
    Beijing, Beijing, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Jun 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2016
First posted
Mar 30, 2016
Start
Aug 2016
Primary completionEst.
Jun 2017
CompletionEst.
Dec 2017
Last update
Sep 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02722694
Responsible party
Sponsor
First posted
Mar 30, 2016
Start date
Aug 2016
Primary completion
Jun 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Sep 13, 2016

Study contacts

Xiaofeng Zeng
Contact
xiaofeng.zeng@cstar.org.cn
86-10-69158793

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion